Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Orvepitant delivers sustained improvements in chronic refractory cough

18 Sep 2019

Treatment with the neurokinin-1 receptor antagonist orvepitant appears to be safe in patients with chronic refractory cough, yielding sustained improvements in cough frequency and severity, according to the results of the phase II VOLCANO-1 trial.

Thirteen patients with daytime cough frequency of >3 to <250 coughs/hour received orvepitant 30 mg once daily for 4 weeks. Objective cough frequency was measured over 24 hours at several time points: baseline and weeks 1, 4, and 8.

The primary outcome was change in daytime cough frequency at week 4. Secondary outcomes included cough severity score on visual analogue scale (VAS), global ratings of change for cough frequency and severity, and Cough-specific Quality of Life Questionnaire score.

Mean objective daytime cough frequency at baseline was 71.4/hour. This improved by 26 percent at week 4, translating to a decrease of 18.9 coughs/hour (95 percent CI, 9.6–28.3; p<0.001).

The improvement was already evident during the first week of treatment (reduction from baseline of 38 percent or 27.0 coughs/hour, 11.4–42.7; p=0.001) and sustained after drug discontinuation through week 8 (reduction of 29 percent or 20.4 coughs/hour, 3.2–37.5; p=0.020). There were significant, parallel improvements seen in severity VAS and quality of life scores.

These findings show that orvepitant merits further clinical investigation, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.